Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases.

• B cell depletion reduces autoimmune disease symptoms but may induce side effects. • Antigen-specific B cell targeted therapies can be solely directed at pathogenic B cells. • CD22, a druggable receptor, is a key target for antigen-specific B cell targeting. • Molecular and cellular platforms may suit antigen-specific B cell targeting. • Antigen-specific targeting can yield insights into the role of autoreactive B cells. Autoimmune diseases are heterogeneous pathologies characterized by a breakdown of immunological tolerance to self, resulting in a chronic and aberrant immune response to self-antigens. The scope and extent of affected tissues can vary greatly per autoimmune disease and can involve multiple organs and tissue types. The pathogenesis of most autoimmune diseases remains unknown but it is widely accepted that a complex interplay between (autoreactive) B and T cells in the context of breached immunological tolerance drives autoimmune pathology. The importance of B cells in autoimmune disease is exemplified by the successful use of B cell targeting therapies in the clinic. For example, Rituximab, a depleting anti-CD20 antibody, has shown favorable results in reducing the signs and symptoms of multiple autoimmune diseases, including Rheumatoid Arthritis, Anti-Neutrophil Cytoplasmic Antibody associated vasculitis and Multiple Sclerosis. However, Rituximab depletes the entire B cell repertoire, leaving patients susceptible to (latent) infections. Therefore, multiple ways to target autoreactive cells in an antigen-specific manner are currently under investigation. In this review, we will lay out the current state of antigen-specific B cell inhibiting or depleting therapies in the context of autoimmune diseases. [ABSTRACT FROM AUTHOR]